Aurinia Pharmaceuticals Inc. (AUPH) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aurinia Pharmaceuticals Inc. (AUPH:NASDAQ), powered by AI.

Current Price
$16.22
P/E Ratio
7.6
Market Cap
2.2B
Sector
Healthcare
What is the Aurinia Pharmaceuticals Inc. stock price forecast?

Aurinia Pharmaceuticals Inc. is currently trading at $16.22. View real-time AI analysis on Alpha Lenz.

What is Aurinia Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Aurinia Pharmaceuticals Inc. on Alpha Lenz.

What is Aurinia Pharmaceuticals Inc.'s P/E ratio?

Aurinia Pharmaceuticals Inc.'s P/E ratio is 7.6.

Aurinia Pharmaceuticals Inc.

NASDAQ · AUPH
$16.22+0.22(+1.37%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Aurinia Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Aurinia Pharmaceuticals Inc. trades at a P/E of 7.6 (undervalued) with strong ROE of 59.9%. 3Y revenue CAGR of 28.3% highlights clear growth momentum.

Ask for details

Company Overview

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of novel therapies for the treatment of autoimmune diseases. The company's primary function is to advance therapeutic options that improve the lives of individuals suffering from debilitating autoimmune conditions. A standout feature of Aurinia Pharmaceuticals is its specialization in nephrology, which includes its flagship product designed to treat lupus nephritis, a severe manifestation of systemic lupus erythematosus impacting kidney function. Aurinia's research and development efforts concentrate on innovative drug platforms, leveraging scientific advancements to address unmet medical needs in the immune system disorders arena. As a key player in the biotech industry, Aurinia Pharmaceuticals contributes to significant advancements in personalized medicine and targeted therapy. By pushing the boundaries of conventional treatment options, the company plays a crucial role in expanding the horizons of autoimmune disease management within global healthcare markets.

CEOMr. Peter S. Greenleaf M.B.A.
SectorHealthcare
IndustryBiotechnology
Employees130

Company Statistics

FY 2025

Profile

$2.18BMarket Cap
$283.06MRevenue
0.00Shares Out
130Employees

Margins

88.46%Gross
49.31%EBITDA
37.65%Operating
40.33%Pre-Tax
101.47%Net

Valuation

7.59P/E
3.75P/B
7.70EV/Sales
15.58EV/EBITDA
16.10P/FCF

Growth (CAGR)

28.30%Rev 3Yr
41.38%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

44.11%ROA
59.91%ROE
18.20%ROIC

Financial Health

$80.21MCash & Cash Equivalents
$90.04MNet Debt
29.29%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Aurinia Pharmaceuticals Inc. (ticker: AUPH) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 130 employees. Market cap is $2.2B.

The current price is $16.22 with a P/E ratio of 7.59x and P/B of 3.75x.

ROE is 59.91% and operating margin is 37.65%. Annual revenue is $283M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Aurinia Pharmaceuticals Inc. (AUPH) Stock Forecast 2026 $16.22 — Price, Financials & Analyst Targets | Alpha Lenz